Korean J Anesthesiol.  1989 Aug;22(4):545-550. 10.4097/kjae.1989.22.4.545.

Anesthetic Management for 12 Patients with Myasthenia Gravis

Affiliations
  • 1Department of Anesthesiology, Hanyang University, College of Medicine, Seoul, Korea.
  • 2Department of Anesthesiology, College of Medicine, Soon Chun Hyang University, Seoul, Korea.

Abstract

Serious complications and death may occur in patients with neuromuscular disorders after administration of muscle relaxants that include prolonged paralysis, hyperkalemia, muscle rigidy and malignant hyperthermia. Myasthenia gravis, neuromuscular junctional lestion, is a postsynaptic autoimmune disease that reduces the acetylcholine receptor population. Those with myasthenia gravis like patients with other neuromuscular disorders respond abnormally to administration of depolarizing and non-depolarizing neuromuscular blocking agents. Therefore, many anesthesiologists avoid the use of muscle relaxants in general anesthesia for these patients, but the use of volatile anesthetics, premedicants, anticholiesterases and other drugs also have drawbacks. Special precautions should be taken with patients with myasthenia gravis to avoid interaction of muscle relaxants and other drugs at the neuromuscular junction in the anesthetic management during surgery and perioperative serious complications.

Keyword

Myasthenia gravis; Muscle relaxants; Anticholinesterase; Neuromuscular junction

MeSH Terms

Acetylcholine
Anesthesia, General
Anesthetics
Autoimmune Diseases
Humans
Hyperkalemia
Malignant Hyperthermia
Myasthenia Gravis*
Neuromuscular Blocking Agents
Neuromuscular Junction
Paralysis
Acetylcholine
Anesthetics
Neuromuscular Blocking Agents
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr